International Symposium On Hepatic Encephalopathy

International Symposium on Hepatic Encephalopathy. September 2009.

General Information

Meeting venue

The International Symposium on Hepatic Encephalopathy will be held in the Santiago Grisolía Auditorium in the Museo de las Ciencias Príncipe Felipe of Valencia (Spain). The museum, designed by Valencian architect Santiago Calatrava, and with an auditorium of 2.800 square metres, provides the perfect venue for this symposium.

These emblematic projects have turned Valencia, with its heritage of over two thousand years of history, into a most modern city. The city is easily accessible by road, rail, sea and air. Its culture, cuisine and academic tradition along with its location on the Mediterranean coast and its pleasant climate, make the city the ideal setting for this symposium.

Auditorium Santiago Grisolía
Science Museum Príncipe Felipe
Av. Autopista del Saler, 7
46013 Valencia, Spain

The Science Museum Príncipe Felipe is in the dry river bed Turia. From the centre of the city it can be easily reached by taxi in 10 minutes. Buses number 19 and 35 from the City Hall square takes about 15 minutes.

Program

The symposium will start on Thursday 17th early in the morning and it will finish on Saturday 19th in the afternoon.

“Andres T. Blei Lecture”
Roger F. Butterworth. Hôpital Saint-Luc C.H.U.M. Montreal, Canada.
Cerebral inflammation in liver failure.

Mechanisms of ammonia toxicity
Susanne Keiding. Aarhus University Hospital. Aarhus, Denmark.
Brain ammonia and energy metabolism in hepatic encephalopathy. Analysis by positron emission tomography.

Dieter Häussinger. Heinrich-Heine-Universität. Düsseldorf, Germany.
Oxidation of RNA in hyperammonemia and hepatic encephalopathy.

Michael D. Norenberg. University of Miami School of Medicine. Miami, USA.
Role of NF-kB in ammonia toxicity.

Jan Albrecht. Medical Research Center, Polish Academy of Sciences. Warsaw, Poland.
Mechanisms of cell protection in ammonia neurotoxicity.

Magdalena Zielinska. Medical Research Center, Polish Academy of Sciences. Warsaw, Poland.
Modulation of the NO-cGMP pathway by glutamine.

Neurotransmission
Sophie Lotersztajn. Inserm U955, Hôpital Henri Mondor. Créteil, France.
The cannabinoids system in liver disease and hepatic encephalopathy.

Samir Ahboucha. Hôpital Saint-Luc C.H.U.M. Montreal, Canada.
The neurosteroids system in hepatic encephalopathy.

Javier Saez-Valero. Universidad Miguel Hernández-CSIC. Alicante, Spain.
Brain cholinergic alterations in liver failure. Role in cognitive function.

Vicente Felipo. Centro de Investigación Príncipe Felipe. Valencia, Spain.
Selective regional alterations in GABAergic tone in brain in chronic hyperammonemia in vivo. Role in cognitive impairment.

Cerebral edema
Alejandro A. Rabinstein. Mayo Clinic, Rochester. Minnesota, USA.
Cerebral edema: types, mechanisms and treatments.

Rodrigo Jover. Hospital General de Alicante. Alicante, Spain.
Vasogenic and cytotoxic edema in patients with acute, chronic or acute on chronic liver disease.

Omar Cauli. Centro de Investigación Príncipe Felipe. Valencia, Spain.
Vasogenic and cytotoxic edema in brain in animal models of acute or chronic hepatic encephalopathy and hyperammonemia.

N. Jan Shah. Forschungszentrum Jülich GmbH. Jülich, Germany.
Quantitative cerebral water content mapping in hepatic encephalopathy

Rakesh K. Gupta. SGPGIMS. Lucknow, India.
Advances in the Magnetic resonance imaging in patients with liver failure and hepatic encephalopathy.

Acute liver failure
Juan Cordoba. Hospital Vall d’Hebron. Barcelona. Spain
Metabonomic analysis of hepatic encephalopathy progression during acute liver failure

Finn S. Larsen. Rigshospitalet University Hospital of Copenhagen. Copenhagen, Denmark.
Cerebral hemodynamic alterations in acute liver failure. Underlying mechanisms and role in death.

Rajiv Jalan. Royal Free and University College Medical School. London, UK.
Brain inflammation in acute liver failure and its relationship with intracranial hypertension and death.

Regina Rodrigo. Centro de Investigación Príncipe Felipe. Valencia, Spain.
Acute liver failure-induced death of rats is delayed or prevented by blocking NMDA receptors in brain.

Julia Wendon. King's College Hospital. London, UK.
Intensive care management of acute liver failure.

Neurological alterations
Andrea Kelly. Children's Hospital of Philadelphia. Philadelphia, USA
Hyperinsulinism/hyperammonemia syndrome: alterations in cerebral function and molecular mechanisms.

Christopher O. Record. Newcastle Upon Tyne Hospitals NHS Trust. Newcastle Upon Tyne, UK.
Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt insertion.

Andrea Stracciari. S. Orsola-Malpighi University Hospital. Bologna, Italy.
Cognitive functioning in chronic acquired hepatocerebral degeneration.

Karin Weissenborn. Medizinische Hochschule Hannover. Hannover, Germany.
Cognitive alterations in patients with hepatic encephalopathy.

Marsha Morgan. The UCL Institute of Hepatology. London, UK.
Alterations in sleep and in circadian rhythms in patients with liver disease.

Jasmohan S. Bajaj. Virginia Commonwealth University and McGuire VA Medical Center. Richmond VA, USA.
Minimal hepatic encephalopathy and daily life.

Piero Amodio. University of Padova. Padova, Italy.
Electroencephalographic staging of hepatic encephalopathy.

Treatments
Andrew A. M. Morris. Royal Manchester Children’s Hospital. Manchester, UK.
Neonatal hyperammonemia, main causes and treatment.

Rajiv Jalan. Royal Free and University College Medical School. London, UK.
Ornithine-phenylacetate for the treatment of hyperammonemia and hepatic encephalopathy.

Mariano Malaguarnera. University of Catania. Catania, Italy.
Probiotics and acetylcarnitine in the treatment of minimal hepatic encephalopathy.

Manuel Romero-Gómez. Hospital Universitario de Valme. Sevilla, Spain.
Rifaximin for the treatment of hepatic encephalopathy